Background and design -Australia has the highest rates of skin cancer in the world, and the incidence is estirnated to be doubling every 10 years. Despite advances in the early detection and treatment of melanoma about 800 people still die nationally of the disease each year. A possible strategy for further reducing the mortality from melanoma is an organised programme of population screening for unsuspected lesions in asymptomatic people. Arguments against introducing melanoma screening have been based on cost and the lack of reliable data on the efficacy of any screening tests. To date, however, there has been no systematic economic assessment of the cost effectiveness of melanoma screening. The purpose of this research was to determine whether screening may be potentially cost effective and, therefore, warrants further investigation. A computer was used to simulate the effects of a hypothetical melanoma screening programme that was in operation for 20 years, using cohorts of Australians aged 50 at the start of the programme. Based on this simulation, cost-effectiveness estimates of melanoma screening were calculated. Results -Under the standard assumptions used in the model, and setting the sensitivity of the screening test (visual inspection of the skin) at 60%, cost effectiveness ranged from Aust$6853 per life year saved for men ifscreening was undertaken five yearly to $12137 ifscreening was two yearly. For women, it ranged from $11102 for five yearly screening to $20877 for two yearly screening. Conclusion -The analysis suggests that a melanoma screening programme could be cost effective, particularly if five yearly screening is implemented by family practitioners for men over the age of 50.
Australia has the highest incidence of skin cancer in the world.' In 1989 the age standardised incidences of melanocytic skin cancer (cutaneous invasive malignant melanoma or melanoma) were 30'23 and 23·86 per 100 000 person years for men and women respectively, with a marked latitudinal gradient; for example the male incidence in 1989 was 47·26 in the Northern Territory and Queensland versus 19·84 in Victoria and Tasmania."
Although the disease can be diagnosed by visual inspection of the skin, the issue of screening for melanoma is contentious. A recent NIH consensus conference concluded that "there is sufficient evidence to warrant screening programmes for melanoma in the United States" and that "melanoma meets most of the criteria for initiating screening". 3 In contrast, the International Union Against Cancer does not recommend screening." Further, the Australian Cancer Society, which is the leading body for providing recommendations relating to cancer screening in Australia, does not recommend routine screening to Australian doctors," even though the world age standardised incidence of melanoma in Australia is more than twofold that of the United States."! Elwood" has commented that it is difficult to see how the NIH consensus conference reached their conclusions given that a number of the generic characteristics of a good cancer screening programme? have not been satisfied for melanoma. These are: • Screening should be highly sensitive and specific • The prevalence of the disease should be high enough to warrant screening • The health implications should be serious enough to warrant screening • The disease screened for should be one that is slowly advancing and not immediately life threatening • The screening procedure should be simple, inexpensive, and acceptable to the population being screened • The screened disease should be one for which early diagnosis results in improved prognosis • Screening should lead to more effective treatment at an earlier stage.
Screening should be highly sensitive and specific Elwood has examined this in detail and concludes that the "performance of the screening test for melanoma (visual inspection of the skin) in a general population is unknown". 6 There are data on the sensitivity and specificity of visual inspection of the skin for the diagnosis ofmelanoma for dermatologists and skin cancer specialists in a variety of settings. Koh et al reported sensitivities (73-89%) and specificities (92-98%) for screening by doctors, dermatologists, and skin cancer specialists in hospital settings in the USA and commented "whether such values apply for the practising physician in the community is unknown". B Subsequently Koh et al reported on dermatologists "screening" self referred subjects at screening centres in Massachusetts, USA, where the sensitivity for diagnosis of melanoma was estimated to be 97%. 9 Recently, a study by Grin et alhas reported an overall sensitivity of80'8% and specificity of99·2% over 27 years of screening by dermatologists in a general outpatient dermatology clinic at a skin and cancer unit." The only data on screening a non-selected asymptomatic population come from a survey of the incidence and prevalence of skin cancer in Geraldton, Western Australia, where over 4103 people aged 40-64 were screened by dermatologists. 11 Suspected melanoma was diagnosed in 36 and a further 68 were diagnosed as suspicious pigmented lesions in subjects who subsequently had their lesions excised and examined by a pathologist. Of the 36 suspected melanomas, 12 were confirmed by histology and two of the 68 suspicious pigmented lesions were also melanomas. A total of 701 lesions were excised in this population and submitted for histopathology, with a total of 20 melanomas being diagnosed. Given lack of data, we have assumed that these were all ofthe melanomas in this population and, hence, the upper limit of the sensitivity of dermatologists screening this population for melanoma and suspicious pigmented lesions is 70% and the specificity is 98%. For melanoma alone the sensitivity is 60%, but it should be noted that any screening programme for melanoma would be for both melanoma and suspicious pigmented lesions. This was a research study, however, and not a routine population screening programme for the disease.
As it is not practicable to undertake screening of larger populations using only skin cancer specialists, the sensitivity and specificity of other potential screeners -self screening by the public, trained non-medical health professionals, and primary health care physicians -needs to be ascertained before the cost effectiveness of screening by any of these groups can be calculated accurately.
The prevalence of the disease should be high enough to warrant screening Data from Australian Cancer registries show that melanoma is the fourth commonest cancer in men and the third commonest cancer in women, and that Australia has the highest incidence in the world. 1 12
The health implications should be serious enough to warrant screening In 1991 melanoma killed 799 Australians as compared with 313 killed by carcinoma of the cervix, for which there is a national screening policy; melanoma ranked tenth as a cause of death from cancer in that year."
The disease screenedfor should be one that is slowly advancing and not immediately life threatening Based on the mean or median age at diagnosis, estimates of six to 16 years for the time to progress from thin curable lesions «I'OOmm thick, >90% 15 year survival) to thick potentially fatal melanomas (>3 mm thick, <50% 15 year survival) have been obtained in various populations. 13-16 Girgis, Clarke, Burton, Sanson-Fisher These estimates are subject to a number of errors, such as the relative proportions of superficial spreading, nodular and lentigo malignant melanomas in each population, 14 cohort effects,' accuracy of histopathological diagnosis and measurement of depth, 17 and the proportion of progressive versus non-progressive melanomas." These may, in part, explain the wide range of estimates and this cautions against their uncritical acceptance.
The screening procedure should be simple, inexpensive, and acceptable to the population being screened Visual inspection of the skin is simple and, as shown by attendance at mole check clinics made available free of charge to the general public in various countries, it is generally acceptable to various populations. 6719 The expense of screening is unknown and modelling of the potential costs of population screening is an aim of this report.
The screened disease should be one for which early diagnosis results in improved prognosis
Survival data from the largest published study of primary cutaneous invasive melanoma, which included 6515 patients in Australia and the USA, 16 show that the 15 year absolute survivals after resection of melanomas of various thicknesses are: >90% for melanomas of <0'76 mm thickness, >80% for 0,76-1,49 mm, 65% for 1·50-2·49 mm, 50% for 2,50-3·99 mm, and <40% for >4·0 mm.
Given the factors which influence estimates for the time of progress discussed earlier, one cannot assume that a screening programme which increases the proportion of thin to thick melanomas diagnosed in a population must result in commensurate improvement in cure rates. However, down-staging has been a feature of successful screening programmes for breast and bowel cancer 2021 and so an absolute reduction in the incidence of thicker melanomas in a screened population should translate into improved survival from the disease in that population. Decreases in the proportion, and stabilisation in the incidence of thicker melanomas, have been observed in populations subjected to intensive education campaigns to increase early diagnosis of the disease. 19 22 23 Screening should lead to more effective treatment at an earlier stage There are, as yet, no published randomised control trials that have tested whether screening reduces population mortality from melanoma, though several possible randomised controlled trial designs have been proposed." Until randomised controlled trial data become available, Koh et al have advocated analysing "all available information to evaluate the potential benefits (and costs) of current efforts"." WHO SHOULD BE SCREENED?
It has been argued that the cost of general population screening could be prohibitive, and this has led to the suggestion that selective screening of high risk individuals may be preferable to screening the general population. 6
The purpose of selective screening is to reduce the cost by only screening individuals with a higher risk of developing melanoma and, hence, requires the presence of risk markers which enable patients to be readily identified as being at a higher risk of melanoma than the general population. Koh et al have suggested that the high risk groups include white persons with one or more of the following risk factors: dysplastic naevi, a positive family history, fair complexion and light skin, propensity for sunburn, and a changing mole." However, English has recently reported age as being the strongest independent risk factor for developing melanoma, using data collected from a case-control study (8th Scientific meeting of the International Epidemiological Association of Sydney, 1993). Given the relative difficulty of identifying people with the risk factors described by Koh et al,B it may be argued that age is the most cost-effective risk variable to identify people for inclusion in a melanoma screening programme.
There are additional data to justify the use of age as a single determinant for selective population screening. Age specific trends in melanoma mortality worldwide indicate that only in the age group over SO is mortality still increasing." Furthermore, in the Hunter area of New South Wales, analysis of the characteristics of patients diagnosed with melanomas >3·0 mm thick in the 1980s showed that 76% were aged SO or older and that 68% were men." One of the consequences of a general population screening programme would be the diagnosis of many very thin melanomas which probably have little competence for metastasis," thus adding to the cost without any accompanying benefits. Hence, restricting a screening programme to that section of the population which is most at risk of dying from the disease would reduce the impact of this outcome of screening on the benefits versus costs.
WHO SHOULD PROVIDE THE SCREENING?
If the screening test is to be cost effective, it needs to be provided by readily accessible health care providers. Although one can argue that self screening is potentially cost effective, it is likely that it would function merely as a first level of screening and that the burden of subsequent diagnosis and management would fall on primary health care physicians. Therefore, it seems pertinent for the purposes of this analysis to focus on primary health care physicians, who not only have the potential to perform opportunistic screening for melanoma on patients attending their practice for other purposes but also to take part in population screening programmes. For example, about 76% of men over the age of 45 visited a primary health care physician at least once a year." Thus an opportunistic screening programme, or a selective population screening programme, could access this high risk group through their primary health care physician.
Furthermore, although the sensitivity and specificity of screening for melanoma by primary health care physicians is unknown, for the purposes of a screening programme the crucial de-49 cision is whether a skin lesion should be biopsied or not, and Australian research indicates that doctors are able to determine this accurately."
The purpose of the research reported here is to undertake an analysis of the relative cost effectiveness of opportunistic screening of an older subset ofthe population by primary health care physicians. Although such an analysis should ideally be based on data from randomised controlled trials, no trial of a mass population based melanoma screening programme has been conducted to date." In the place ofdata from a clinical trial, the researchers have estimated the potential benefits of screening using an interactive computer modelling process which analyses screening options using the best available data. It is hoped that the results of this research, although only providing broad estimates of the cost effectiveness of screening, may help to guide a clinical trial by identifying the important parameters that influence cost effectiveness.
Methods

THE KNOX MODEL
Computer methods for predicting the outcome of population screening have been widely used to estimate the benefits of screening for other cancers." The computer program used to model melanoma screening in this study was developed by Knox" and has been used by the Australian Institute of Health to estimate outcomes for the evaluation of breast and cervical cancers. 3132 The Knox model is a steady state model that simulates the effect of a screening programme that has been in operation for 15-20 years. The benefits of introducing a screening programme into a previously unscreened population cannot be quantified using the model (Stevenson CE, et al, Annual conference of the Public Health Association of Australia, 1990 ). The Knox model has been used in preference to other cancer screening models" because it is easier to calibrate using the currently available information on melanoma.
All computer modelling was performed on a hypothetical cohort of men and women aged SO at the start of a hypothetical programme of screening which began in 1992, and simulated the effects of melanoma screening to be conducted over the next 20 years (1992-2012). The screening programme should be seen as supplementing existing arrangements for the early detection of melanoma. This means that the benefit estimates represent the reduction in mortality of those who currently die from melanoma. Hence, the model only estimates the potential additional benefits from screening over the existing care.
The Knox model divides the natural history of the cancer into two successive periods, designated "A" and "B", whereby during period A the cancer is susceptible to early detection and cure, and in period B the cancer is incurable. The length of these periods can be varied to reflect the fact that the course of the disease will not be the same for all people. Allowance can also be made for increasing These data facilitate the measurement of benefits flowing from reducing the current mortality from melanoma. The 1989 Australian population profile" was used in the economic evaluation to estimate life years saved. It is assumed that the same population structure was maintained over the life of the programme.
(b) Estimates of the duration of periods A and B
The estimates of the rate of progression of melanoma were obtained from the data on mean or medium age diagnosis versus thickness described earlier. The mean value of period A was assumed to be five years, which is at the lower end of the published estimates; and period B was assumed to be one year to reflect the low survival rate of patients with final stage melanoma. Given the uncertainty over the rates of progression, a 50% variability of these parameters was also incorporated into the model. More rapid progression was also examined in the sensitivity analysis.
(c) Sensitivity and specificity of the test
The sensitivity of screening by primary health care physicians is dependent upon two factors: the ability of the practitioner to identify suspicious skin lesions and the accuracy of the histopathology. As there has been no large scale trial of primary health care physician based melanoma screening, we have used a range of assumptions for sensitivity and specificity. The value of adopting such an approach is that it allows us to determine if melanoma screening could potentially be cost effective if the sensitivity and specificity of a real screening programme were to fall within this range.
Although it is likely that primary health physician based screening will have a sensitivity Girgis, Clarke, Burton, Sanson-Fisher lower than the 73-97% for dermatologists at specialist clinics," and the 60% sensitivity obtained by dermatologists who screened the Geraldton population," there are no data on exactly how much lower. To overcome this problem we adopted two values for sensitivity that reflect the potential difficulties of implementing a general practitioner based visual skin examination. As a lower bound we used 30% and as an upper bound we used 60% sensitivity in all our analyses. Without a randomised controlled trial there are insufficient data to reduce the range of these estimates.
We assumed a 98% specificity based on the Geraldton study, II because these are the only data available on screening a non-selected asymptomatic population. As screening by a primary health care physician may also have a lower specificity we lowered this to 90% in our sensitivity analysis.
(d) Therapeutic efficacy of the treatment
The survival rate of patients detected by the screening programme during period A was based on the survival data referred to previously." Using these data, it was assumed that the survival rate declined from 93% to 40% over the duration of period A. Patients detected in period B were assumed to receive no benefit from the melanoma screening.
(e) Acceptance rates for the test by different age groups Given the lack of randomised controlled trials, there are no data on acceptance rates for a visual skin examination in the general population. To gauge the likely rate we examined data on the rate of women participating in cervical cancer screening programmes, which in Australia are largely provided by primary health care physicians. Health Insurance Commission data indicate that 62% of women aged between 20 and 69 had been screened at least once in the three year period 1987 to 1989. 32 In line with these data we assumed a 60% participation rate in screening, which is likely to be conservative as visual skin examination is less invasive than a Pap smear.
TARGET GROUPS CONSIDERED FOR SCREENING
As previously argued, targeting the screening programme at high risk individuals is likely to be the most cost-effective strategy. Given the risk differential, this study examined the cost effectiveness of screening men and women separately, as the number of deaths due to melanoma varies with sex. For the purposes of analysis we used men and women aged 50, as the mortality from melanoma in Australia increases rapidly after that age (Giles GG et al, unpublished data), and published literature supports targeting the older age group." Although this age group has been used as an illustrative example in this analysis, a similar procedure could be used in the future to estimate the cost effectiveness of screening other age categories.
SCREENING INTERVALS CONSIDERED
The screening interval is a crucial factor in determining the cost effectiveness of screening, with the optimal length of the interval based on the rate of progression of the melanoma. Two screening intervals were examined in the analysis: every five years and every two years.
COSTS OF SCREENING
All costs relating to the procedures used in a melanoma screening and treatment programme were estimated using the 1992 Australia Medicare benefits schedule." Information on screening time was supplied by the Newcastle melanoma unit (personal communication). It has been assumed that whole body screening of an individual dressed only in underwear takes 10 minutes, or the average length of a standard consultation." Hence the cost of the visual skin examination was estimated to be the cost of a standard length consultation (Aust $23'50). This represents the "opportunity cost" and not the actual cost of the primary health care physician's time.
Lesions which the primary health care physician regards as suspect are generally biopsied and sent for histopathology. The cost of the biopsy of a suspect lesion is estimated to be $67 for removal of the tumour and $70'50 for pathology costs, leading to a total cost of $137·50 ($67+$70'50) for these patients. Patients with a positive histopathology result are assumed to have a melanoma.
Although a proportion of these cases will require further treatment, it is not clear that ongoing treatment costs should be attributed to the screening programme as most of these patients would also be treated for melanoma under existing arrangements. If treatment costs are to be included then the potential savings from earlier detection must also be incorporated into the model. Unfortunately, without a randomised controlled trial, it is impossible accurately to assess the net effect on treatment costs of an organised screening programme. It is important to note that given the small number of cases treated relative to the total population screened, the net treatment costs are likely to have negligible effect on the cost effectiveness of a screening programme. To simplify matters we assumed no net treatment costs in the model. This assumption is tested in the sensitivity analysis. Our calculations are based on men and women aged 50 at the start of a 20-year screening programme, which is assumed to start in 1992. All costs are expressed in 1992 Australian dollars and benefits measured as percentage of deaths averted. We assume that because the screening is performed by primary health care physicians, there are no significant costs associated with setting up or recruitment for the programme. Both future costs and benefits are discounted at an annual rate of 5% to reflect the common convention in economic analyses of placing greater value on current costs and benefits. 37 We also apply the same discount rate to the health benefits that accrue in the future. Given the likely impact of discount rate assumptions on the cost effectiveness, a sensitivity analysis was undertaken using 3% and 7% discount rates.
Results
Tables 2 and 3 present the cost-effectiveness ratios of screening men and women aged 50. The most cost-effective group to target for screening was men, with the cost per life year saved for five year screening being either $6853 or $11 965 depending on whether 60% or 30% sensitivity of general practitioner screening is assumed. The comparative estimates for women were $11102 and $20002. Screening women was much less cost effective largely because of the lower mortality from melanoma in women." These results also suggest that decreasing the screening interval from five to two years produces a proportional increase in costs, but a less than proportional increase in percentage of deaths averted. This raises the cost per life year saved for men to between $12137 and $18289. The cost effectiveness of screening women will also decline by a similar proportion.
Tables 2 and 3 also provide estimates of the potential benefits in terms of the percentage of deaths averted in the 50 to 75 year age group, and costs to the Australian community of the introduction of such a programme. It should be noted that as period A is five years, there is a potential protective effect for those who develop a melanoma between 70 and 75 years of age. The estimated percentage of deaths averted is based on the assumption of 60% compliance. As we have assumed no set up, both the costs and benefits can be scaled to reflect other rates of compliance.
Tables 2 and 3 also present the average costs per person screened in the 20 year programme. The higher average cost for women can be attributed to the lower mortality in this group and hence, a higher number of screens over the life of the programme.
INCREMENTAL ANALYSIS
An incremental analysis was used to determine the marginal cost effectiveness of reducing the screening interval from five to two years. The marginal cost effectiveness is a ratio of the extra costs to extra benefits that result from a decrease in the screening interval and provides the basis of comparing the cost effectiveness of different screening intervals." The marginal cost effectiveness of decreasing the screening interval from every five years to two years for men was between $28 509 for 30% sensitivity and $25 453 for 60% sensitivity. For women, the comparative incremental cost effectiveness was between $49813 and $51757 per extra life year saved. This higher marginal cost results from the small increase in the number of life years saved. The high marginal cost suggests that reducing the screening interval from every two years comes at a substantial decrease in the cost effectiveness of the screening programme. Whether such a reduction represents value for money can only be determined with reference to the total health budget and cost effectiveness of other programmes.
SENSITIVITY ANALYSIS
Given the uncertainty surrounding some of the medical evidence which was used to estimate the cost effectiveness of screening, sensitivity analysis has been applied to several key assumptions. Sensitivity analysis involves reworking the model using different assumptions to determine the impact of this on the costeffectiveness estimates relative to a baseline case. A programme to screen men and women every five years was chosen as the "baseline" case against which the various assumptions were compared. The rate of sensitivity was assumed to be 60%, though the relative magnitude of the other changes over this baseline would be similar for other rates of sensitivity. Table 4 reports the change in the cost-effectiveness ratios over this baseline case. The assumptions were varied as follows: (a) The specificity of the test was lowered from 98% to 90%, as it may be expected that this variable would be lower when screening asymptomatic individuals. (b) The length of period A was decreased from five to two years. (c) As the exact discount rate that should be applied to health projects is difficult to determine, we tested the effect of altering the discount rate by applying a 3% and a 7% discount rate to the model. The higher the rate of discount the more society values present as against future health gains. (fi) A net cost of $10 000 was assumed per treated case. Although this represents an overestimate of net cost, it is designed to show the impact of treatment costs on the overall cost effectiveness of the programme.
Of all the assumptions tested, the model was most sensitive to variation in the length of period A. Lowering this length from five to two years more than doubled the cost per life year saved. Further research on the rate of progression of melanoma is dearly needed for an accurate cost-effectiveness analysis to be undertaken.
Discussion
The aim of this research was to undertake an analysis of the cost effectiveness of primary health care physicians screening different subsets of the population for melanoma. There are potential benefits of undertaking such an analysis. Early detection and treatment oflesions is currently one of the effective strategies available for combating melanoma. However, to date, systematic screening has not been recommended in Australia, and is unlikely to be until results are available from a well controlled trial which sheds light on the efficacy of the screening test itself. It is hoped that the results of the economic analysis reported here show that such a trial is worth undertaking in that there is a prima facie case for melanoma screening.
These results suggest that a melanoma screening programme could potentially be cost effective. Furthermore, screening men was the most cost-effective strategy identified in the economic analysis, at a total cost of $6853 per life year saved, compared with $11102 for the equivalent screening for women of the same age and at the same interval, assuming a sensitivity of 60% for the screening test. A number of issues need to be considered in both interpreting the economic results presented here, and in considering implementing a screening programme.
HOW DOES THIS COMPARE WITH OTHER
SCREENING PROGRAMMES?
The cost-effectiveness estimates may vary with the type of computer model used to simulate the health benefits from screening. Carter et al " found significant differences in the estimated benefits from breast cancer screening by using the MISCAN as opposed to the Knox model. However, the central issue of whether melanoma screening represents value for money cannot be answered in absolute terms, but only by comparison with other cancer screening programmes. The Australian Institute of Health and Welfare has conducted similar economic assessments for breast and cervical cancers using the Knox model to estimate the health outcomes of national screening programmes. The estimated cost of screening women for breast cancer is between $6000 and $11 000 per life year saved," and $30782 for cervical cancer screening." It should be emphasised that comparison of these estimates with those calculated here for melanoma screening are tentative because these studies used similar, but not identical, methodologies. However, on the basis of these estimates, screening older men for melanoma may potentially be as cost effective as screening women for breast cancer, and screening women for melanoma may be more cost effective than screening them for cervical cancer.
OPPORTUNISTIC VERSUS SYSTEMATIC SCREENING
The current cost-effectiveness estimates are based on opportunistic screening by primary health care physicians of those patients attending their practice who are in the recommended age group. Given data which indicate that about 76% of men aged over 45 visited a primary health care physician in a 12 month period (1990-1991),27 the majority of the target population could be effectively accessed through opportunistic screening by their primary health care physician. This negates the need for a more systematic screening programme and, hence, reduces the overall costs of implementing screening. A more systematic screening programme would require estimates of the recruitment costs as well as estimates of the resultant increase in the proportion of the population screened.
COSTS OF IMPLEMENTING A SCREENING
PROGRAMME
The actual costs of a screening programme as discussed in this paper are likely to be higher owing to the detection of other non-melanocytic skin cancers while screening for melanoma. Although the additional costs associated with detecting and treating these lesions may be substantial, they should not be attributed to the current programme under consideration, but should be evaluated separately relative to the benefits that are derived from removal of these cancers.
VALIDITY OF ASSUMPTIONS
As indicated previously, a number of assumptions were made in calculating the cost-effectiveness estimates. Although it is acknowledged that some ofthese assumptions may not be accurate, steps were taken to account for these possible inaccuracies when estimating the cost effectiveness. As data were not available on the sensitivity and specificity of the screening test in a general population, estimates of these variables were reduced to reflect a lowered sensitivity and specificity when screening asymptomatic individuals.
In conclusion, the present economic analysis suggests that a melanoma screening programme which targets Australian men aged 50 for five yearly screening by primary health care physicians may be potentially cost effective relative to current screening programmes for other cancers. It is hoped that the results of' this analysis will provide valuable information which may help to define some of the parameters for a well controlled trial of the efficacy of screening by primary health care physicians. 
